272 related articles for article (PubMed ID: 16691061)
21. Noncomparative contraceptive efficacy of cellulose sulfate gel.
Mauck CK; Freziers RG; Walsh TL; Peacock K; Schwartz JL; Callahan MM
Obstet Gynecol; 2008 Mar; 111(3):739-46. PubMed ID: 18310379
[TBL] [Abstract][Full Text] [Related]
22. Desired qualities and hypothetical contextual use of vaginal microbicides in a diverse sample of US women.
Olsen ML; Cwiak CA; Koudelka C; Jensen JT
Contraception; 2007 Oct; 76(4):314-8. PubMed ID: 17900444
[TBL] [Abstract][Full Text] [Related]
23. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States.
Mayer KH; Peipert J; Fleming T; Fullem A; Moench T; Cu-Uvin S; Bentley M; Chesney M; Rosenberg Z
Clin Infect Dis; 2001 Feb; 32(3):476-82. PubMed ID: 11170957
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of an acidic vaginal gel on vaginal pH and interleukin-6 levels in low-risk pregnant women: a double-blind, randomized placebo-controlled trial.
Paternoster DM; Tudor L; Milani M; Maggino T; Ambrosini A
J Matern Fetal Neonatal Med; 2004 Mar; 15(3):198-201. PubMed ID: 15280147
[TBL] [Abstract][Full Text] [Related]
25. Safety evaluation of 1% tenofovir gel in healthy men.
Schwartz JL; Poindexter A; Wheeless A; Mauck CK; Callahan MM
Int J STD AIDS; 2009 Jun; 20(6):384-6. PubMed ID: 19451321
[TBL] [Abstract][Full Text] [Related]
26. Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050).
Carballo-Diéguez A; Balán IC; Morrow K; Rosen R; Mantell JE; Gai F; Hoffman S; Maslankowski L; El-Sadr W; Mayer K
AIDS Care; 2007 Sep; 19(8):1026-31. PubMed ID: 17852000
[TBL] [Abstract][Full Text] [Related]
27. User experiences and acceptability attributes of the diaphragm and lubricant gel in an HIV prevention trial in southern Africa.
Sahin-Hodoglugil NN; Montgomery E; Kacanek D; Morar N; Mtetwa S; Nkala B; Philip J; Ramjee G; Cheng H; van der Straten A; The Mira Team
AIDS Care; 2011 Aug; 23(8):1026-34. PubMed ID: 21480005
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria.
Halpern V; Ogunsola F; Obunge O; Wang CH; Onyejepu N; Oduyebo O; Taylor D; McNeil L; Mehta N; Umo-Otong J; Otusanya S; Crucitti T; Abdellati S
PLoS One; 2008; 3(11):e3784. PubMed ID: 19023429
[TBL] [Abstract][Full Text] [Related]
29. A Phase I study of the functional performance, safety and acceptability of the BufferGel Duet.
Ballagh SA; Brache V; Mauck C; Callahan MM; Cochon L; Wheeless A; Moench TR
Contraception; 2008 Feb; 77(2):130-7. PubMed ID: 18226678
[TBL] [Abstract][Full Text] [Related]
30. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults.
Schürmann D; Fätkenheuer G; Reynes J; Michelet C; Raffi F; van Lier J; Caceres M; Keung A; Sansone-Parsons A; Dunkle LM; Hoffmann C
AIDS; 2007 Jun; 21(10):1293-9. PubMed ID: 17545705
[TBL] [Abstract][Full Text] [Related]
31. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women.
Van Damme L; Wright A; Depraetere K; Rosenstein I; Vandersmissen V; Poulter L; McKinlay M; Van Dyck E; Weber J; Profy A; Laga M; Kitchen V
Sex Transm Infect; 2000 Apr; 76(2):126-30. PubMed ID: 10858715
[TBL] [Abstract][Full Text] [Related]
32. The impact of microbicides and changes in condom usage on HIV prevalence in men and women.
Chen FH
AIDS; 2006 Jul; 20(11):1551-3. PubMed ID: 16847411
[TBL] [Abstract][Full Text] [Related]
33. Africa, India test sites for anti-HIV microbicide. Cellulose sulfate tested in high-risk women.
AIDS Alert; 2005 Mar; 20(3):34-6. PubMed ID: 15789474
[TBL] [Abstract][Full Text] [Related]
34. Vaginal microbicides: moving ahead after an unexpected setback.
van de Wijgert JH; Shattock RJ
AIDS; 2007 Nov; 21(18):2369-76. PubMed ID: 18025873
[No Abstract] [Full Text] [Related]
35. Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa.
van de Wijgert JH; Braunstein SL; Morar NS; Jones HE; Madurai L; Strickfaden TT; Moodley M; Aboobaker J; Ndlovu G; Ferguson TM; Friedland BA; Hart CE; Ramjee G
J Acquir Immune Defic Syndr; 2007 Dec; 46(5):538-46. PubMed ID: 18193495
[TBL] [Abstract][Full Text] [Related]
36. Acceptability of vaginal film, soft-gel capsule, and tablet as potential microbicide delivery methods among African women.
Nel AM; Mitchnick LB; Risha P; Muungo LT; Norick PM
J Womens Health (Larchmt); 2011 Aug; 20(8):1207-14. PubMed ID: 21774672
[TBL] [Abstract][Full Text] [Related]
37. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women.
Mayer KH; Karim SA; Kelly C; Maslankowski L; Rees H; Profy AT; Day J; Welch J; Rosenberg Z;
AIDS; 2003 Feb; 17(3):321-9. PubMed ID: 12556685
[TBL] [Abstract][Full Text] [Related]
38. Expanded safety study of Praneem polyherbal vaginal tablet among HIV-uninfected women in Pune, India: a phase II clinical trial report.
Joshi SN; Dutta S; Kumar BK; Katti U; Kulkarni S; Risbud A; Mehendale S
Sex Transm Infect; 2008 Oct; 84(5):343-7. PubMed ID: 18426844
[TBL] [Abstract][Full Text] [Related]
39. Acceptability and adherence: findings from a Phase II study of a candidate vaginal microbicide, 'Praneem polyherbal tablet', in Pune, India.
Joglekar NS; Joshi SN; Deshpande SS; Parkhe AN; Katti UR; Mehendale SM
Trans R Soc Trop Med Hyg; 2010 Jun; 104(6):412-5. PubMed ID: 20096909
[TBL] [Abstract][Full Text] [Related]
40. Vaginal microbicides.
O'Brien RF
Adolesc Med Clin; 2006 Oct; 17(3):673-85; abstract xi. PubMed ID: 17030285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
